All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Zanubrutinib receives EC approval for the treatment of R/R marginal zone lymphoma
Bookmark this article
On November 2, 2022, it was announced that the European Commission had granted approval to zanubrutinib, a Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior line of anti-CD20-based therapy.1
The approval follows a positive opinion granted by the European Medicine Agency’s Committee for Medicinal Products for Human Use in September of this year and is based on key results of the phase II MAGNOLIA trial (NCT03846427). In the trial, zanubrutinib demonstrated a high overall response rate and acceptable safety in marginal zone lymphoma, consistent with its established profile.
- Business Wire. BeiGene receives European Commission approval for BRUKINSA® (zanubrutinib) for the treatment of adults with marginal zone lymphoma. https://www.businesswire.com/news/home/20221102005244/en/BeiGene-Receives-European-Commission-Approval-for-BRUKINSA%C2%AE-zanubrutinib-for-the-Treatment-of-Adults-with-Marginal-Zone-Lymphoma. Published Nov 2, 2022. Accessed Nov 3, 2022.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox